drugset / Trial / NCT05273554
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.
Timeline
- Start
- 2022-08-31
- Primary completion
- 2026-09-22
- Completion
- 2026-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |